JP5814467B2 - キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 - Google Patents
キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 Download PDFInfo
- Publication number
- JP5814467B2 JP5814467B2 JP2014519977A JP2014519977A JP5814467B2 JP 5814467 B2 JP5814467 B2 JP 5814467B2 JP 2014519977 A JP2014519977 A JP 2014519977A JP 2014519977 A JP2014519977 A JP 2014519977A JP 5814467 B2 JP5814467 B2 JP 5814467B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- imidazo
- phenyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014519977A JP5814467B2 (ja) | 2012-06-04 | 2013-06-03 | キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012127079 | 2012-06-04 | ||
| JP2012127079 | 2012-06-04 | ||
| PCT/JP2013/065328 WO2013183578A1 (ja) | 2012-06-04 | 2013-06-03 | キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体 |
| JP2014519977A JP5814467B2 (ja) | 2012-06-04 | 2013-06-03 | キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP5814467B2 true JP5814467B2 (ja) | 2015-11-17 |
| JPWO2013183578A1 JPWO2013183578A1 (ja) | 2016-01-28 |
Family
ID=49711970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519977A Active JP5814467B2 (ja) | 2012-06-04 | 2013-06-03 | キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 |
Country Status (32)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102224153B (zh) | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| LT3106463T (lt) | 2008-10-22 | 2018-06-25 | Array Biopharma, Inc. | Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| PT3205654T (pt) | 2010-05-20 | 2019-04-22 | Array Biopharma Inc | Compostos macrocíclicos como inibidores de cinases trk |
| CN104470918A (zh) | 2012-05-30 | 2015-03-25 | 日本新药株式会社 | 芳香族杂环衍生物及医药 |
| CN106132967B (zh) * | 2014-03-27 | 2019-05-28 | 詹森药业有限公司 | 作为ros1抑制剂的化合物 |
| AU2015238296B2 (en) * | 2014-03-27 | 2018-10-18 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors |
| CA2946416C (en) * | 2014-04-25 | 2022-07-19 | Exelixis, Inc. | Method of treating lung adenocarcinoma |
| AU2015346046B2 (en) | 2014-11-16 | 2020-06-25 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| MA41667A1 (fr) | 2015-06-01 | 2018-08-31 | Loxo Oncology Inc | Procede de diagnostic et de traitement du cancer |
| BR112017027339A2 (pt) | 2015-06-18 | 2018-09-04 | Cephalon, Inc. | derivados de piperidina 1,4-substituída |
| CA3014432C (en) | 2015-06-18 | 2024-05-07 | Cephalon, Inc. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| EA035049B1 (ru) | 2015-07-16 | 2020-04-22 | Аррэй Байофарма Инк. | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| CN106854174A (zh) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | 一种4位取代哌啶衍生物的制备方法 |
| EP3439663B1 (en) | 2016-04-04 | 2024-07-17 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| SI3800189T1 (sl) | 2016-05-18 | 2023-11-30 | Loxo Oncology, Inc. | Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| CN107400082A (zh) * | 2016-05-19 | 2017-11-28 | 湖南华腾制药有限公司 | 一种取代哌啶衍生物的制备方法 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CA3049136C (en) | 2017-01-18 | 2022-06-14 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
| CA3055504A1 (en) * | 2017-03-14 | 2018-09-20 | Daiichi Sankyo Company, Limited | Method for producing 3,6-disubstituted imidazo[1,2-b]pyridazine derivative |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| CN109748902B (zh) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | 一种盐酸安罗替尼的制备方法 |
| KR102078775B1 (ko) * | 2017-11-29 | 2020-02-19 | 서울대학교산학협력단 | 항-ros1 항체 및 그의 용도 |
| CN108129288B (zh) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | 一种反式-3-羟基环丁基甲酸的合成方法 |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| US12037345B2 (en) | 2018-07-24 | 2024-07-16 | Taiho Pharmaceutical Co., Ltd. | Heterobicyclic compounds for inhibiting the activity of SHP2 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| WO2020179859A1 (ja) * | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| CA3142088C (en) * | 2019-05-08 | 2023-02-28 | Tyk Medicines, Inc. | Compound used as kinase inhibitor and application thereof |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202200589A (zh) * | 2020-05-28 | 2022-01-01 | 瑞士商諾華公司 | Ｍｌｌ１抑制劑及抗癌劑 |
| CN114957259A (zh) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | 氰基取代的芳香双环类化合物及其应用 |
| CA3223035A1 (en) * | 2021-07-01 | 2023-01-05 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof |
| WO2023220967A1 (en) * | 2022-05-18 | 2023-11-23 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds |
| CN114989176B (zh) * | 2022-07-08 | 2024-08-27 | 深圳市新樾生物科技有限公司 | 咪唑并哒嗪类衍生物及其应用 |
| CN115197115B (zh) * | 2022-08-25 | 2024-11-08 | 成都金博汇康医药科技有限公司 | 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用 |
| AU2023339247A1 (en) | 2022-09-07 | 2025-03-27 | Suzhou Langrui Biopharmaceutical Co., Ltd. | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof |
| CN117659020A (zh) * | 2022-09-07 | 2024-03-08 | 苏州朗睿生物医药有限公司 | 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| EP1339680A1 (en) | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| EP1317446A1 (en) | 2000-09-01 | 2003-06-11 | Glaxo Group Limited | Oxindole derivatives |
| JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| EP1742921A2 (en) | 2004-04-21 | 2007-01-17 | AstraZeneca AB | Pyrazole derivatives useful for the treatment of cancer |
| US20080167314A1 (en) * | 2004-12-28 | 2008-07-10 | Osamu Uchikawa | Condensed Imidazole Compound And Use Thereof |
| HUE025671T2 (en) | 2005-02-04 | 2016-04-28 | Astrazeneca Ab | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| PL1853602T3 (pl) | 2005-02-16 | 2010-11-30 | Astrazeneca Ab | Związki chemiczne |
| US8129403B2 (en) | 2005-02-16 | 2012-03-06 | Astrazeneca Ab | Chemical compounds |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| US7776878B2 (en) * | 2005-08-01 | 2010-08-17 | Hoffmann-La Roche Inc. | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| DE102006029447A1 (de) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| MX2009004700A (es) * | 2006-11-06 | 2009-05-15 | Supergen Inc | Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa. |
| WO2008072682A1 (ja) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| JP2009227599A (ja) * | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| ES2548135T3 (es) | 2008-05-13 | 2015-10-14 | Novartis Ag | Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa |
| CN102224153B (zh) * | 2008-09-22 | 2014-04-30 | 阵列生物制药公司 | 作为trk激酶抑制剂的取代的咪唑并[1，2-b]哒嗪化合物 |
| KR101147550B1 (ko) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| WO2012005299A1 (ja) | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Ｒｏｓチロシンキナーゼ阻害剤 |
| WO2012125667A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
-
2013
- 2013-05-31 TW TW102119261A patent/TWI585088B/zh active
- 2013-06-03 EP EP13801320.6A patent/EP2857404B1/en active Active
- 2013-06-03 MX MX2014014803A patent/MX357021B/es active IP Right Grant
- 2013-06-03 CN CN201380041498.XA patent/CN104520300B/zh active Active
- 2013-06-03 SG SG11201408052WA patent/SG11201408052WA/en unknown
- 2013-06-03 HU HUE13801320A patent/HUE037221T2/hu unknown
- 2013-06-03 ES ES13801320.6T patent/ES2648228T3/es active Active
- 2013-06-03 WO PCT/JP2013/065328 patent/WO2013183578A1/ja not_active Ceased
- 2013-06-03 HR HRP20171724TT patent/HRP20171724T1/hr unknown
- 2013-06-03 IN IN2497MUN2014 patent/IN2014MN02497A/en unknown
- 2013-06-03 NZ NZ702574A patent/NZ702574A/en unknown
- 2013-06-03 PL PL13801320T patent/PL2857404T3/pl unknown
- 2013-06-03 LT LTEP13801320.6T patent/LT2857404T/lt unknown
- 2013-06-03 KR KR1020147033351A patent/KR101781255B1/ko active Active
- 2013-06-03 CA CA2874819A patent/CA2874819C/en active Active
- 2013-06-03 RS RS20171198A patent/RS56625B1/sr unknown
- 2013-06-03 BR BR112014029851-3A patent/BR112014029851B1/pt active IP Right Grant
- 2013-06-03 US US14/378,318 patent/US9187489B2/en active Active
- 2013-06-03 NO NO13801320A patent/NO2857404T3/no unknown
- 2013-06-03 SI SI201330798T patent/SI2857404T1/sl unknown
- 2013-06-03 MY MYPI2014003346A patent/MY170326A/en unknown
- 2013-06-03 JP JP2014519977A patent/JP5814467B2/ja active Active
- 2013-06-03 DK DK13801320.6T patent/DK2857404T3/en active
- 2013-06-03 PT PT138013206T patent/PT2857404T/pt unknown
- 2013-06-03 RU RU2014153627A patent/RU2635917C2/ru active
- 2013-06-03 SM SM20170539T patent/SMT201700539T1/it unknown
- 2013-06-03 AU AU2013272701A patent/AU2013272701B2/en active Active
-
2014
- 2014-12-02 ZA ZA2014/08843A patent/ZA201408843B/en unknown
- 2014-12-04 IL IL236075A patent/IL236075A/en active IP Right Grant
- 2014-12-04 PH PH12014502721A patent/PH12014502721A1/en unknown
- 2014-12-30 CO CO14286593A patent/CO7160119A2/es unknown
-
2015
- 2015-10-29 US US14/926,973 patent/US9751887B2/en active Active
-
2017
- 2017-11-15 CY CY20171101204T patent/CY1119607T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5814467B2 (ja) | キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 | |
| JP7033764B2 (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| JP6494622B2 (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 | |
| JP6267231B2 (ja) | カゼインキナーゼ１δ／ε阻害剤としての新規な置換イミダゾール | |
| JP7549597B2 (ja) | Ｅｅｄおよびｐｒｃ２調節物質としての大環状アゾロピリジン誘導体 | |
| JP7723666B2 (ja) | 環式化合物およびその使用方法 | |
| EP4389738A1 (en) | Sos1 inhibitor and use thereof | |
| EP3694331B1 (en) | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| EP3601264A1 (en) | Bruton's tyrosine kinase inhibitors | |
| CA3137611A1 (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| WO2015125785A1 (ja) | 複数置換基を有するピラゾロン誘導体 | |
| JP2020525469A (ja) | 新規キノリノン化合物 | |
| EP4141003A1 (en) | Pyrazolo[1,5-a]pyridine derivative, preparation method therefor, and composition and use thereof | |
| JP2016056133A (ja) | 環状構造側鎖を有するピラゾロン誘導体 | |
| HK1207374B (en) | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors | |
| HK1233627A (en) | Serine/threonine kinase inhibitors | |
| HK1233627A1 (en) | Serine/threonine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20150907 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150914 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150917 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5814467 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |